Product Information
ATAZANAVIR SULFATE 300 MG CAP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $2.5602 per EA under NDC 00093552856. Its NADAC has been published 402 times since Mar 21, 2018.
Strength
300 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093552856
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
ATAZANAVIR SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA091673On Market Since
12/27/2017
Pharmacological Classes
Price Statistics
The NADAC for ATAZANAVIR SULFATE 300 MG CAP has been published 402 times since Mar 21, 2018, and over the history we have for it it has declined 90.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.5602 per EA |
|---|---|
| All-time high | $29.0173 (May 16, 2018) |
| All-time low | $1.7959 (Aug 21, 2024) |
| 52-week high | $3.4622 |
| 52-week low | $2.5602 |
| Median price | $5.9101 |
| Average price | $6.9095 |
| Largest weekly change | -43.2% (Sep 19, 2018) |
| Weeks tracked | 402 |
| Tracking since | Mar 21, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the Atazanavir Sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of ATAZANAVIR SULFATE 300 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for ATAZANAVIR SULFATE 300 MG CAP, manufactured by Teva Pharmaceuticals USA Inc., is $2.5602 per EA (NDC 00093552856), effective Jun 24, 2026.
How has the price of ATAZANAVIR SULFATE 300 MG CAP changed over time?
Over the history we have for it, the NADAC for ATAZANAVIR SULFATE 300 MG CAP has declined 90.4%. It has been tracked across 402 weekly CMS publications since Mar 21, 2018.
What are the highest and lowest recorded NADAC prices for ATAZANAVIR SULFATE 300 MG CAP?
Since Mar 21, 2018, the NADAC for ATAZANAVIR SULFATE 300 MG CAP has ranged from a low of $1.7959 (Aug 21, 2024) to a high of $29.0173 (May 16, 2018), with a median of $5.9101 per EA.
Are there cheaper alternatives to ATAZANAVIR SULFATE 300 MG CAP?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of ATAZANAVIR SULFATE 300 MG CAP, so no direct lower-cost alternative is listed.
Who manufactures ATAZANAVIR SULFATE 300 MG CAP?
ATAZANAVIR SULFATE 300 MG CAP (NDC 00093552856) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification